R Damm1,2, T Streitparth3, P Hass4, M Seidensticker3, C Heinze5, M Powerski5, J J Wendler6, U B Liehr6, K Mohnike7, M Pech5, J Ricke3. 1. Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany. robert.damm@med.ovgu.de. 2. Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. robert.damm@med.ovgu.de. 3. Department of Radiology, Ludwig-Maximilians-University Munich, Munich, Germany. 4. Department of Radiation Oncology, Otto-von-Guericke University, Magdeburg, Germany. 5. Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany. 6. Department of Urology, Otto-von-Guericke University, Magdeburg, Germany. 7. Diagnostic and Therapeutic Center am Frankfurter Tor, Berlin, Germany.
Abstract
PURPOSE: In this pilot trial, we investigate the safety of CT-guided high-dose-rate brachytherapy (HDR-BT) as a local ablative treatment for renal masses not eligible for resection or nephrectomy. METHODS: We investigated renal function after irradiation by HDR-BT in 16 patients (11 male, 5 female, mean age 76 years) with 20 renal lesions (renal cell carcinoma n = 18; renal metastases n = 2). Two patients had previous contralateral nephrectomy and two had ipsilateral partial nephrectomy. Six lesions had a hilar localization with proximity to the renal pelvis and would have not been favorable for thermal ablation. Renal function loss was determined within 1 year after HDR-BT by renal scintigraphy and laboratory parameters. Further investigations included CT and MRI every 3 months to observe procedural safety and local tumor control. Renal function tests were analyzed by Wilcoxon's signed rank test with Bonferroni-Holm correction of p-values. Survival and local tumor control underwent a Kaplan-Meier estimation. RESULTS: Median follow-up was 22.5 months. One patient required permanent hemodialysis 32 months after repeated HDR-BT and contralateral radiofrequency ablation of multifocal renal cell carcinoma. No other patient developed a significant worsening in global renal function and no gastrointestinal or urogenital side effects were observed. Only one patient died of renal tumor progression. Local control rate was 95% including repeated HDR-BT of two recurrences. CONCLUSION: HDR-BT is a feasible and safe technique for the local ablation of renal masses. A phase II study is recruiting to evaluate the efficacy of this novel local ablative treatment in a larger study population.
PURPOSE: In this pilot trial, we investigate the safety of CT-guided high-dose-rate brachytherapy (HDR-BT) as a local ablative treatment for renal masses not eligible for resection or nephrectomy. METHODS: We investigated renal function after irradiation by HDR-BT in 16 patients (11 male, 5 female, mean age 76 years) with 20 renal lesions (renal cell carcinoma n = 18; renal metastases n = 2). Two patients had previous contralateral nephrectomy and two had ipsilateral partial nephrectomy. Six lesions had a hilar localization with proximity to the renal pelvis and would have not been favorable for thermal ablation. Renal function loss was determined within 1 year after HDR-BT by renal scintigraphy and laboratory parameters. Further investigations included CT and MRI every 3 months to observe procedural safety and local tumor control. Renal function tests were analyzed by Wilcoxon's signed rank test with Bonferroni-Holm correction of p-values. Survival and local tumor control underwent a Kaplan-Meier estimation. RESULTS: Median follow-up was 22.5 months. One patient required permanent hemodialysis 32 months after repeated HDR-BT and contralateral radiofrequency ablation of multifocal renal cell carcinoma. No other patient developed a significant worsening in global renal function and no gastrointestinal or urogenital side effects were observed. Only one patientdied of renal tumor progression. Local control rate was 95% including repeated HDR-BT of two recurrences. CONCLUSION: HDR-BT is a feasible and safe technique for the local ablation of renal masses. A phase II study is recruiting to evaluate the efficacy of this novel local ablative treatment in a larger study population.
Authors: F A Stewart; J A Te Poele; A F Van der Wal; Y G Oussoren; E M Van Kleef; A Kuin; M Verheij; L G Dewit Journal: Acta Oncol Date: 2001 Impact factor: 4.089
Authors: Florian Streitparth; Maciej Pech; Michael Böhmig; Ricarda Ruehl; Nils Peters; Gero Wieners; Johannes Steinberg; Enrique Lopez-Haenninen; Roland Felix; Peter Wust; Jens Ricke Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-06 Impact factor: 7.038
Authors: Maria C Mir; Cesar Ercole; Toshio Takagi; Zhiling Zhang; Lily Velet; Erick M Remer; Sevag Demirjian; Steven C Campbell Journal: J Urol Date: 2015-01-29 Impact factor: 7.450
Authors: D K Filippiadis; C Gkizas; M Chrysofos; A Siatelis; G Velonakis; E Alexopoulou; A Kelekis; E Brountzos; N Kelekis Journal: Int J Hyperthermia Date: 2017-12-04 Impact factor: 3.914
Authors: Michael Staehler; Markus Bader; Boris Schlenker; Jozefina Casuscelli; Alexander Karl; Alexander Roosen; Christian G Stief; Axel Bex; Berndt Wowra; Alexander Muacevic Journal: J Urol Date: 2014-08-14 Impact factor: 7.450
Authors: Thomas D Atwell; Grant D Schmit; Stephen A Boorjian; Jay Mandrekar; A Nicholas Kurup; Adam J Weisbrod; George K Chow; Bradley C Leibovich; Matthew R Callstrom; David E Patterson; Christine M Lohse; R Houston Thompson Journal: AJR Am J Roentgenol Date: 2013-02 Impact factor: 3.959
Authors: R Houston Thompson; Tom Atwell; Grant Schmit; Christine M Lohse; A Nicholas Kurup; Adam Weisbrod; Sarah P Psutka; Suzanne B Stewart; Matthew R Callstrom; John C Cheville; Stephen A Boorjian; Bradley C Leibovich Journal: Eur Urol Date: 2014-08-06 Impact factor: 20.096
Authors: J Ricardo Rivero; Jose De La Cerda; Hanzhang Wang; Michael A Liss; Ann M Farrell; Ronald Rodriguez; Rajeev Suri; Dharam Kaushik Journal: J Vasc Interv Radiol Date: 2018-01 Impact factor: 3.464